Insights

The rapid, at home COVID-19 antigen test from digital diagnostics company Ellume features core technology from Cambridge Consultants. Read how this FDA approved test is set to be a game changer in the global pandemic.

Walking the floor at CES, physically or virtually, can be overwhelming for anyone. The choice of solutions seems endless. If you're part of a consumer goods company, one that was born before the digital revolution, how do you navigate it?

The urgent sustainability imperative is prompting a maze of evolving regulatory requirements in housebuilding. Thermal performance in new builds is mandated by regulations – yet there is currently no commercially viable verification method.

Driven by advances in silicon and machine learning algorithms, Edge AI is presenting vast opportunities for businesses across diverse markets. 

Telemedicine is where telecommunication and healthcare converge.

Nathan Wrench, Head of Sustainability at Cambridge Consultants, joins Gulf Intelligence to discuss how to spur climate targets in 2021 while juggling economic recovery from Covid-19.

The ophthalmology world is welcoming a new wave of sophisticated implant technology designed to transform diagnosis and treatment.

Dan Cowen, Senior Consultant at Cambridge Consultants, presented at Drug Delivery to the Lungs (DDL) - Christmas Lectures and talked about the path to a sustainable future for inhalation products. Watch his presentation to learn how sustainability in inhalation products can be achieved whilst maintaining safety and efficacy at the core.

We are delighted to report a significant step forward as we grow our bioinnovation capability as we have received our licence from the UK Human Tissue Authority to store human tissue for research purposes. This opens the way to future development in cell therapies and regenerative medicine. 

Sustainability emerged as a hot and emotive topic at this year’s Drug Delivery to the Lungs (DDL) conference, read Donal Taylor's thoughts on other key trends that emerged.

Only two companies at the top of the Fortune 500 have survived from 20 years ago. The newcomers have risen by being fleet of foot or riding a financial or technological wave.

Matt Garwood challenges the medical device development status quo. If we embrace a bold, comprehensive response that begins at the concept stage and ends with the device user, it is possible to challenge conventional thinking and change for the better.